Protocol Design Featured Articles

  1. When One Trial Leads To Rethinking Them All 7/22/2026

    A chance observation during the COVID-19 pandemic led physician-scientist Dan Nicolau to question one of clinical research's oldest assumptions. I spoke with Nicolau about the trial that changed his perspective and why he believes continuous trial analytics could reshape the future of clinical development.

  2. The U.S. Clinical Trial Recruiting Pipeline Report – June 2026 7/22/2026

    This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from May 1 to June 30, 2026.

  3. Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors 7/20/2026

    CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.

  4. The Promise Of Bispecifics In The Quest For Outpatient Immunotherapy 7/15/2026

    START San Antonio's Drew Rasco, MD, reflects on the evolution of immunotherapy and highlights how novel therapies such as bispecifics are both challenging and intriguing for principal investigators (PIs).

  5. Digital Twins Enhance Disease Progression Measurements In FSHD 7/14/2026

    Digital twins can transform trial design by making data more robust and alleviating patient burden. In this interview, Epicrispr CEO Amber Salzman, Ph.D., shares how the company's using it to reliably predict muscle volume change in their trial for a FSHD gene therapy. 

  6. Navigating The New EU Pharmaceutical Legislation: Key Implications For Pediatric Drug Development 7/13/2026

    UCB’s Senior Development Strategy Lead Pediatrics Martine Dehlinger-Kremer, Ph.D., discusses updates to the new EU Pharma legislation and how they impact pediatric drug development, including earlier pediatric investigational plans .

  7. Beyond The IND Clock: What Operation TrialBlazer Gets Right — And Where It Stalls (Part 1) 7/10/2026

    The FDA's Operation TrailBlazer includes a proposal to speed up IND review and approval. But will it work? Kimberly Chew and Odette Hauke identify where the initiative succeeds and where the structural gaps begin.

  8. Beyond The IND Clock: The Legal Architecture Of QRIs And What Industry Must Say Before July 22 (Part 2) 7/10/2026

    The FDA's Operation TrailBlazer includes a proposal to speed up IND review and approval. But Kimberly Chew and Odette Hauke say its legal architecture is unresolved and reveals compliance issues that are hard to ignore.

  9. Before AI Can Transform Clinical Trials, It Needs More Patient Data 7/7/2026

    King’s College London Professor Maddy Parsons says AI won't improve clinical trials — unless researchers begin collecting richer biological data, embracing diversity, and treating every clinical trial as learning opportunity.

  10. How One Researcher's Personal Study Experience Is Helping Him Better Serve Patients 7/6/2026

    Regeneron Executive Director in Clinical Sciences Kaniel Cassady, Ph.D., reflects on how his industry experience shaped his expectations, questions, and interactions as a patient in a clinical trial and how his patient experience is reshaping his clinical work going forward.